NEDD8 Co-E3 E2-Binding Pocket Inhibitors for Neddylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current understanding of the NEDD8 pathway enzymes and their interactions is limited, hindering the development of therapeutics for cancer and inflammatory diseases, as specific characterization and targeting of these enzymes are needed to effectively inhibit neddylation processes.
Innovation Solution
Identification of a novel binding pocket in NEDD8 co-E3 proteins that interacts with N-terminally acetylated NEDD8 E2 enzymes, allowing for the development of compounds, such as peptides and small molecules, that bind to this pocket to inhibit co-E3 activity, thereby inhibiting neddylation and treating diseases like cancer and inflammatory disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NEDD8 pathway enzymes are targeted for therapeutic development, then treatment efficacy for cancer and inflammatory diseases is improved, but the limited understanding of enzyme interactions increases development difficulty
Solution Approach 1:
The patent segments the NEDD8 pathway into distinct functional components: E1 activating enzyme, E2 conjugating enzyme, E3 ligase, and co-E3 proteins. By identifying and characterizing specific interaction interfaces between these segmented components, the patent reduces the complexity of understanding the entire pathway while maintaining therapeutic efficacy. The focus on the E2-co-E3 interaction interface as a drug target exemplifies this segmentation strategy.
Solution Approach 2:
The patent introduces small molecule compounds as intermediary substances that bind to the co-E3 protein's E2-binding pocket. These intermediaries disrupt the natural E2-co-E3 interaction without requiring complete pathway characterization. The compounds act as molecular mediators that translate the therapeutic intent into specific biochemical disruption of neddylation.
2Measurement precision
If specific characterization of NEDD8 pathway enzymes is pursued, then therapeutic targeting precision is improved, but the complexity of enzymatic pathway analysis increases
Solution Approach 1:
The patent applies local quality by focusing characterization efforts on specific functional domains rather than entire enzymes. The co-E3 protein is analyzed primarily in its PONY domain, which contains the E2-binding pocket. This localized approach provides sufficient precision for therapeutic targeting without requiring complete structural and functional characterization of the entire NEDD8 pathway.
Solution Approach 2:
The patent employs partial action by identifying and characterizing only the essential E2-binding pocket within the co-E3 protein. This partial characterization is sufficient for drug development purposes without the excessive effort of complete pathway enzyme characterization. The approach recognizes that full characterization is unnecessary when the critical interaction interface is identified.
3Productivity
If compounds are designed to bind the E2-binding pocket, then inhibition of neddylation is achieved, but the novelty of the binding site requires extensive validation
Solution Approach 1:
The patent performs preliminary validation by providing computational models of the E2-binding pocket and predicting compound binding modes before extensive experimental validation. The structural characterization and computational analysis prepare the groundwork for subsequent drug screening and optimization, reducing the validation burden during later development stages.
Solution Approach 2:
The patent creates a computational copy or model of the E2-binding pocket structure that can be used for virtual screening and compound design. This digital replica allows extensive testing and validation of compound binding modes without requiring physical interaction studies, thereby reducing experimental validation requirements while maintaining reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The inhibition of NEDD8 co-E3 activity using these compounds effectively targets the neddylation pathway, providing a therapeutic approach for treating cancer, inflammatory disorders, and pathogenic infections by disrupting the neddylation process.
Implementation Method 1
Identification of a novel binding pocket in NEDD8 co-E3 proteins that interacts with N-terminally acetylated NEDD8 E2 enzymes
Data Source
AI summary
Provided herein is a novel binding pocket within NEDD8 co-E3 proteins that binds NEDD8 E2 enzymes. Particularly at its M-Terminus. Methods are provided for screening for compounds that bind to the disclosed E2-binding pocket in NEDD8 co-E3 proteins. Compounds that bind to the E2-binding pocket and optionally inhibit the activity of NEDD8 co-E3 proteins and pharmaceutical compositions comprising the same are further provided. The NEDD8 co-E3 inhibitors find use, as agents preventing the NEDDylation of a target protein, in inhibiting cell growth and methods for treating cancers, inflammatory disorders, and pathogenic infections. The preferred inhibitors are peptides corresponding to a M-terminal fragment of Dnc1, e.g. MTLASKLKRDD, MLKLRQLQKKKQ, and MIKLFSLKQQKK, which are substituted at the M-Terminus with an uncharged group (e.g. acyl).